Providers should refer to the package insert for recommended dose modifications and management in the event of an adverse reaction (see Table 1).1 Drug Interactions CYP3A inhibitors (e.g., itraconazole, erythromycin, fluconazole, diltiazem) may increase acalabrutinib toxicity, whereas inducers (e....
Calquence [package insert] (2022) AstraZeneca Pharmaceuti- cals, Wilmington. DE 6. Calquence [summary of product characteristics] (2020) Astra- Zeneca UK Limited. Bedfordshire, United Kingdom 7. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Kam- dar M, Munir T, Walewska R, ...